These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37288137)

  • 1. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
    El-Ghazzi N; Durando X; Giro A; Herrmann T
    Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.
    Rousset-Rouviere S; Rochigneux P; Chrétien AS; Fattori S; Gorvel L; Provansal M; Lambaudie E; Olive D; Sabatier R
    Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
    Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
    Front Oncol; 2022; 12():844801. PubMed ID: 35494078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".
    Gadducci A; Cosio S
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-driven therapy in endometrial cancer.
    Karpel H; Slomovitz B; Coleman RL; Pothuri B
    Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for endometrial cancer.
    Wada M; Yamagami W
    Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38913219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
    Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
    Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
    Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.
    Tinker AV; Dhani NC; Ghatage P; McLeod D; Samouëlian V; Welch SA; Altman AD
    Ther Adv Med Oncol; 2023; 15():17588359231157633. PubMed ID: 36950270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
    Mittica G; Ghisoni E; Giannone G; Aglietta M; Genta S; Valabrega G
    Oncotarget; 2017 Oct; 8(52):90532-90544. PubMed ID: 29163851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
    Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
    Expert Rev Anticancer Ther; 2024 Jun; ():1-13. PubMed ID: 38863432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
    Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
    J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for molecular subtypes of endometrial cancer in 2023.
    Karpel HC; Slomovitz B; Coleman RL; Pothuri B
    Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.
    Johnson RL; Ganesan S; Thangavelu A; Theophilou G; de Jong D; Hutson R; Nugent D; Broadhead T; Laios A; Cummings M; Orsi NM
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series.
    Rose PG; Feldman M; Podzielinski I; Petty AP; Vargas R
    Gynecol Oncol Rep; 2023 Dec; 50():101303. PubMed ID: 38054201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway.
    Luvero D; Cundari GB; Ficarola F; Plotti F; Terranova C; Montera R; Bogani G; Silvagni A; Celoro F; Angioli R
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.